Deep Track Biotechnology Master Fund, Ltd. - 06 Aug 2026 Form 4 Insider Report for Attovia Therapeutics, Inc. (ATTO)

Reporting relationship: 10%+ Owner
Issuer ticker: ATTO
Reported as of: 06 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Aug 2026, 16:30:11 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin, Director

Key filing fact

Deep Track Biotechnology Master Fund, Ltd. filed Form 4 for Attovia Therapeutics, Inc. (ATTO) on 10 Aug 2026.

Key facts

This page summarizes Deep Track Biotechnology Master Fund, Ltd.'s Form 4 filing for Attovia Therapeutics, Inc. (ATTO).
2 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 10 Aug 2026, 16:30.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0002015536 Primary reporting owner

Deep Track Biotechnology Master Fund, Ltd.

Relationship: 10%+ Owner
Address: C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVE, GEORGE TOWN, CAYMAN ISLANDS
Signature: Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin, Director
Signature date: 10 Aug 2026

CIK 0001856083

Deep Track Capital, LP

Relationship: 10%+ Owner
Address: 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH
Signature: Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser
Signature date: 10 Aug 2026

CIK 0001397513

KROIN DAVID

Relationship: 10%+ Owner
Address: C/O DEEP TRACK CAPITAL, LP, 200, GREENWICH AVENUE, 3RD FLOOR, GREENWICH
Signature: /s/ David Kroin
Signature date: 10 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,957,138
Change %
Price
Shares after: 1,957,138
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,957,138
Change %
Price
Shares after: 1,957,138
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,957,138
Change %
Price
Shares after: 1,957,138
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATTO transaction Derivative

Series C Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -18,181,818
Change %
Price: $0.000000^*
Shares after: $0
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,957,138
Exercise price
Footnotes: F1, F2

ATTO transaction Derivative

Series C Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -18,181,818
Change %
Price: $0.000000^*
Shares after: $0
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,957,138
Exercise price
Footnotes: F1, F2

ATTO transaction Derivative

Series C Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -18,181,818
Change %
Price: $0.000000^*
Shares after: $0
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,957,138
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Deep Track Biotechnology Master Fund, Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.

Footnote F2

Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .